A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)

NCT06977724 · tracked via the Priya Life Science France tracker

Sponsor

AbbVie

Phase

Phase 1

Started

2025-08-26

Last updated

2026-08-10

Condition(s) studied

Dry Eye SyndromeSystemic Lupus Erythematosus

Investigational drug(s) / intervention(s)

ABBV-319 →

ABBV-319: Intravenous (IV) Infusion

Study summary

Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disease characterized by B cell hyperactivity. Sjorgren's disease (SjD) is a chronic, multisystem autoimmune disease characterized by lacrimal and salivary gland inflammation, with resultant dryness of the eyes and mouth and occasional glandular enlargement and Rheumatoid arthritis (RA) is a long-lasting autoimmune disease that causes the body's immune system to attack itself. RA targets the body's joints, causing inflammation (swelling, pain, and redness). ABBV-319 exhibits potential B cell depletion in SLE, SjD and RA which are characterized by B cell hyperactivity. The purpose of this study is to assess the pharmacokinetics, safety, and efficacy of ABBV-319 in adult participants with SLE, SjD and RA.

ABBV-319 is an investigational drug being developed for the treatment of SLE , SjD and RA. Participants are placed in 1 of 8 groups called treatment arms. Each group receives a different dose of ABBV-319 depending on whether they have SLE, SjD or RA. Around 48 adult participants with SLE, SjD or RA will be enrolled at approximately up to 17 sites worldwide.

Participants will receive 2 doses of IV ABBV-319 21 days apart and will be followed for up to 343 days.

There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Eligibility

Sex

ALL

Min age

18 Years

Max age

75 Years

Healthy volunteers

Inclusion Criteria: * Systemic Lupus Erythematosus (SLE) Population - Clinical diagnosis of SLE at least 6 months prior to Screening as defined by the 2019 European Alliance of Associations for Rheumatology (EULAR)/American College Of Rheumatology (ACR) classification criteria for SLE and a positive antinuclear antibody (ANA) \>= 1:80 drawn at Screening. * SLE Population - Anti-double stranded DNA (dsDNA), anti-Smith (Sm), anti-ribonucleoprotein (RNP), or anti-Sjogren's syndrome Ag A (SSA) Abs above the upper limit of normal (ULN). * Sjogren's Disease (SjD) Population - Primary diagnosis of SjD at least 6 months prior to Screening as defined by the ACR/EULAR 2016 Criteria. * SjD Population - EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) \>= 5 at Screening. * SjD Population - EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) \>= 5 at Screening. * Rheumatoid Arthritis (RA) Population - Clinical diagnosis of RA and fulfilling the 2010 ACR/EULAR classification criteria for RA. * RA Population - Rheumatoid Factor (RF) or ACPA above the ULN at Screening. * RA Population - Confirmation of at least moderate disease activity at Screening, defined by both of the following disease activity criteria: * Presence of at least 6 swollen and 6 tender joints at Screening using the 68 (tender)/66 (swollen) joint count. * hs-CRP ≥3 mg/L. Exclusion Criteria: * History of infection as defined in the protocol. * Any of the medical diseases or disorders listed in the protocol. * History of clinically significant (per investigator's judgment) drug or alcohol abuse within the 6 months prior to Screening. * Any planned elective surgery that would impact study procedures or assessments through the completion of the Day 365 assessments. * Any clinically significant ECG abnormalities at Screening. * RA-Specific Exclusion Criteria - History of RA overlap syndromes, including but not limited to, SLE, SjD, scleroderma, mixed connective tissue disease, or polymyositis.

Primary outcome measure(s)

Number of Participants with Adverse Events (AEs) — Up to approximately 400 days
An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Change from Baseline in B Cells in Blood and Tissue — Up to approximately 400 days
Change from baseline in B cells in blood and tissue.
Maximum Plasma Concentration (Cmax) of ABBV-319 — Up to approximately 400 days
Cmax of ABBV-319.
Time to Cmax (Tmax) of ABBV-319 — Up to approximately 400 days
Tmax of ABBV-319.
Terminal Phase Elimination Half-Life (t1/2) of ABBV-319 — Up to approximately 400 days
t1/2 of ABBV-319.
Area Under the Concentration-Time Curve From Time 0 to Last Measurable Concentration (AUCt) of ABBV-319 — Up to approximately 400 days
AUCt of ABBV-319.
Percentage of Participants with Detection of Anti-Drug Antibodies (ADAs) for ABBV-319 — Up to approximately 400 days
Percentage of participants with detection of ADAs for ABBV-319.
Percentage of Participants with Detection of Neutralizing Antibodies (nAbs) for ABBV-319 — Up to approximately 400 days
Percentage of participants with detection of nAbs for ABBV-319.

Trial sites (11)

Facility	City	Region	Status
Highlands Advanced Rheumatology And Arthritis Center - Avon Park /ID# 278239	Avon Park	Florida	Not Yet Recruiting
Clinical Research Of West Florida - Phase I Unit /ID# 275834	Clearwater	Florida	Not Yet Recruiting
Life Clinical Trials - Colonial Drive - Margate /ID# 276050	Margate	Florida	Recruiting
Clinical Research Of West Florida - Tampa - North Howard Avenue /ID# 275836	Tampa	Florida	Recruiting
Advanced Quality Medical Research /ID# 278462	Orland Park	Illinois	Recruiting
Private Practice - Dr. Ramesh C. Gupta /ID# 275826	Memphis	Tennessee	Recruiting
Integrative Rheumatology of South Texas - Harlingen /ID# 276458	Harlingen	Texas	Recruiting
Les Hopitaux Universitaires de Strasbourg - Hopital de Hautepierre /ID# 272692	Strasbourg	Alsace	Recruiting
CHU de Montpellier - Hopital Lapeyronie /ID# 279892	Montpellier	Herault	Recruiting
Amsterdam University Medical Center /ID# 274286	Amsterdam	North Holland	Recruiting
Universitair Medisch Centrum Utrecht /ID# 273398	Utrecht	Netherlands	Recruiting

More AbbVie trials in France

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma Active, not recruiting

Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis Recruiting

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Active, not recruiting

Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN Active, not recruiting

Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Recruiting

Other trials for the same condition

A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) Active, not recruiting

Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) Active, not recruiting

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus Active, not recruiting

A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD) Recruiting

HLA Antibodies in Systemic Lupus Erythematosus Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06977724 on ClinicalTrials.gov ↗ ← All trials in France